From these in-vitro results, BCR-ABL-inactivated CML cells stimulated γδT expansion and cytotoxicity via IPP, although zoledronate was more potent than BCR-ABL inhibitors. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.